A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Lal, Jessica Castrillon; Brown, Sherry-Ann; Collier, Patrick; Cheng, Feixiong

doi:10.1186/s40959-021-00106-x

Cardio-Oncology

Table 2 Complete analysis of all cardiac AE risk from immunotherapy versus chemotherapy

From: A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Adverse Event	Therapy	*OR (95% CI)*	*q-value*
Pericarditis	Combination v chemo	0.61 (0.23, 1.67)	0.339
	Combination v aCTLA4	1.79 (0.39, 8.3)	0.457
	Combination v aPD1L1	0.48 (0.24, 0.97)	0.04
	aPD1L1 v chemo	1.28 (0.6, 2.72)	0.523
	aCTLA4 v chemo	0.34 (0.07, 1.66)	0.184
	aCTLA4 v aPD1L1	0.27 (0.07, 1.1)	0.068
Myocardial Infarction	Combination v chemo	0.42 (0.29, 0.6)	< 0.001
	Combination v aPD1L1	0.94 (0.72, 1.24)	0.671
	Combination v aCTLA4	0.75 (0.5, 1.14)	0.178
	aPD1L1 v chemo	0.44 (0.34, 0.58)	< 0.001
	aCTLA4 v chemo	0.56 (0.36, 0.85)	0.007
	aCTLA4 v aPD1L1	1.25 (0.87, 1.79)	0.219
Heart Failure	Combination v chemo	0.38 (0.27, 0.54)	< 0.001
	Combination v aPD1L1	0.84 (0.65, 1.08)	0.171
	Combination v aCTLA4	2.21 (1.22, 3.9)	< 0.001
	aPD1L1 v chemo	0.46 (0.36, 0.59)	< 0.001
	aCTLA4 v chemo	0.17 (0.1, 0.32)	< 0.001
	aCTLA4 v aPD1L1	0.38 (0.22, 0.66)	< 0.001
Coronary Artery Disease	Combination v chemo	0.64 (0.37, 1.12)	0.12
	Combination v aCTLA4	1.47 (0.59, 3.63)	0.405
	Combination v aPD1L1	0.96 (0.6, 1.52)	0.848
	aPD1L1 v chemo	0.67 (0.47, 0.96)	0.028
	aCTLA4 v chemo	0.44 (0.18, 1.06)	0.066
	aCTLA4 v aPD1L1	0.65 (0.28, 1.49)	0.309
Arrhythmias	Combination v CTLA4	0.92 (0.7, 1.23)	0.584
	Combination v chemo	0.71 (0.61, 0.84)	< 0.001
	Combination v aPD1L1	1.06 (0.89, 1.26)	0.531
	aPD1L1 v chemo	0.67 (0.61, 0.73)	< 0.001
	aCTLA4 v chemo	0.77 (0.61, 0.98)	0.035
	aCTLA4 v aPD1L1	1.15 (0.89, 1.47)	0.289
Myocarditis	Combination v aPD1L1	1.41 (1.08, 1.85)	0.012
	Combination v chemo	30.76 (18.42, 51.37)	< 0.001
	Combination v aCTLA4	3.93 (1.89, 8.16)	< 0.001
	aPD1L1 v chemo	21.81 (13.89, 34.24)	< 0.001
	aCTLA4 v chemo	7.83 (3.41, 18)	< 0.001
	aCTLA4 v aPD1L1	0.36 (0.18, 0.73)	0.005

Shown is the logistic regression model data of the entire dataset, cases are not matched; Combination indicates more than one immunotherapy was administered. Adjusted p-values (q-value) is displayed
aPD1L1 = anti- Programmed cell death protein - 1 and Programmed death ligand -1; aCTLA4 = cytotoxic T-lymphocyte- associated proteni 4

Back to article page

ISSN: 2057-3804

Contact us

General enquiries: journalsubmissions@springernature.com